Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011 (2011), Article ID 829751, 4 pages
http://dx.doi.org/10.1155/2011/829751
Review Article

The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis

1Department of Clinical Immunology, University Hospital Alexandrovska, 1 G. Sofiiski Street, 1431 Sofia, Bulgaria
2Department of Dermatovenereology, Varna Medical University, 55 M. Drinov Street, 9000 Varna, Bulgaria

Received 12 June 2011; Revised 28 August 2011; Accepted 28 August 2011

Academic Editor: Eswar Krishnan

Copyright © 2011 Marta Baleva and Krasimir Nikolov. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. Dalakas, I. Illa, J. M. Dambrosia et al., “A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis,” New England Journal of Medicine, vol. 329, no. 27, pp. 1993–2000, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Shoenfeld and I. Krause, “IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients,” Journal of Clinical Immunology, vol. 24, no. 2, pp. 107–114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Jolles, “High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders,” Clinical and Experimental Immunology, vol. 129, no. 3, pp. 385–389, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. Bystryn, D. Jiao, and S. Natow, “Treatment of pemphigus with intravenous immunoglobulin,” Journal of the American Academy of Dermatology, vol. 47, no. 3, part A1, pp. 358–363, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. A. R. Ahmed and M. V. Dahl, “Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases,” Archives of Dermatology, vol. 139, no. 8, pp. 1051–1059, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Bodemer, D. Teillac, M. Le Bourgeois, B. Wechsler, and Y. de Prost, “Efficacy of intravenous immunoglobulins in sclerodermatomyositis,” British Journal of Dermatology, vol. 123, no. 4, pp. 545–546, 1990. View at Google Scholar · View at Scopus
  7. U. Wollina, A. Looks, R. Schneider, and B. Maak, “Disabling morphoea of childhood—beneficial effect of intravenous immunoglobulin therapy,” Clinical and Experimental Dermatology, vol. 23, no. 6, pp. 292–293, 1998. View at Publisher · View at Google Scholar
  8. Y. Levy, Y. Sherer, P. Langevitz et al., “Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin—a preliminary report,” Clinical Rheumatology, vol. 19, no. 3, pp. 207–211, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Levy, H. Amital, P. Langevitz et al., “Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study,” Arthritis and Rheumatism, vol. 50, no. 3, pp. 1005–1007, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Nacci, A. Righi, M. L. Conforti et al., “Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 977–979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Asano, H. Ihn, N. Asashima et al., “A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion,” Rheumatology, vol. 44, no. 6, pp. 824–826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Szekanecz, M. Aleksza, P. Antal-Szalmás et al., “Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects,” Clinical Rheumatology, vol. 28, no. 3, pp. 347–350, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Blank, Y. Levy, H. Amital, Y. Shoenfeld, M. Pines, and O. Genina, “The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice,” Arthritis and Rheumatism, vol. 46, no. 6, pp. 1689–1690, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Mcgaha, S. Saito, R. G. Phelps et al., “Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4Rα and transforming factor-β genes,” Journal of Investigative Dermatology, vol. 116, no. 1, pp. 136–143, 2001. View at Publisher · View at Google Scholar
  15. G. D. Sempowski, M. P. Beckmann, S. Derdak, and R. P. Phipps, “Subsets of murine lung fibroblasts express membrane-bound and soluble IL- 4 receptors: role of IL-4 in enhancing fibroblast proliferation and collagen synthesis,” The Journal of Immunology, vol. 152, no. 7, pp. 3606–3614, 1994. View at Google Scholar · View at Scopus
  16. K. Amemiya, C. Semino-Mora, R. P. Granger, and M. C. Dalakas, “Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin,” Clinical Immunology, vol. 94, no. 2, pp. 99–104, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Molina, M. Blank, and Y. Shoenfeld, “Intravenous immunoglobulin and fibrosis,” Clinical Reviews in Allergy and Immunology, vol. 29, no. 3, pp. 321–326, 2005. View at Publisher · View at Google Scholar · View at Scopus